Fingolimod (FTY720) HCl

Catalog No.S5002

Fingolimod (FTY720) HCl Chemical Structure

Molecular Weight(MW): 343.9

Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 97 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  •  

     

    Fingolimod blocks antitumor immunity and prevents rejection of myeloma and B-cell lymphoma in TCR-transgenic SCID mice. (A) Id-specific TCR-transgenic (TCR-tg) SCID mice were inoculated subcutaneously with 1.6  105 MOPC315 myeloma cells and treated daily with either fingolimod (FTY720, Selleck Chemicals; 2ug/g bodyweight) or with vehicle only (0.8% DMSO; Sigma-Aldrich) delivered intraperitoneally. Tumor growth was followed by palpation. Mice were euthanized when the tumor reached 10 mm in diameter (n=14-17). (B) Id-specific TCR-transgenic SCID mice were inoculated subcutaneously with 1.6  105 F9 B-lymphoma cells and treated daily with fingolimod or with vehicle only. F9 cells are A20 B-lymphoma cells transfected with Id-containing L-chain from MOPC3157 (n=14-16). (C) Nontransgenic SCID mice were inoculated subcutaneously with 1.6  105 MOPC315 cells and treated daily with fingolimod or with vehicle only (n=8).

    Blood 2012 119, 2176-2177. Fingolimod (FTY720) HCl purchased from Selleck.

     

    Fingolimod blocks antitumor immunity and prevents rejection of myeloma and B-cell lymphoma in TCR-transgenic SCID mice. Id-specific TCR-transgenic and nontransgenic SCID mice were inoculated subcutaneously with 105 MOPC315 myeloma cells embedded in Matrigel.9 TCR-transgenic SCID mice were treated daily with fingolimod (1ug/g bodyweight) or with vehicle only (n=8-10). SCID mice were left untreated (n =2). At day 8, draining lymph nodes and Matrigel plugs were dissected and analyzed by flow cytometry.9 (D) CD69 expression on gated Id-specific CD4 T cells in draining lymph nodes of representative TCR-transgenic SCID mice treated with vehicle only (top) or fingolimod (bottom). Dotted lines indicate an isotype-matched control antibody. (E) Number of Id-specific T cells per Matrigel plug (mean  SEM). (F) Expression of the activation marker MHC class II on Matrigel-infiltrating CD11b macrophages (geometric mean  SEM). P values were calculated with the log-rank test (A-C) and the t test (E-F). ns indicates not significant.

    Blood 2012 119, 2176-2177. Fingolimod (FTY720) HCl purchased from Selleck.

  • FTY720 treatment of ECM decreases lymphocyte numbers and granzyme A mRNA in the brain. (A) Relative CD8+ and (B) CD4+ T-cell numbers isolated from the brains of mice infected for 6 d. Numbers were decreased in animals treated with FTY720 1 d before infection and 1 d p.i. (CD4+: P < 0.5 and P < 0.001, CD8+: P < 0.5 and P < 0.01 respectively, KW and DMC, two pooled IE, n ≥ 4/group/IE) (C) GZMA mRNA levels were decreased in the brains of FTY720-treated animals compared with control animals: for (FTY720 [–1], P < 0.05, FTY720 [+1] P > 0.05 and FTY720 [+3], P < 0.01; KW and DMC, two pooled IE, n ≥ 3/group/IE).

    Mol Med 2011 17, 717- 725 . Fingolimod (FTY720) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective S1P Receptor Inhibitors

Biological Activity

Description Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.
Targets
S1P receptor [1]
(K562, NK cells )
0.033 nM
In vitro

The inhibitory effect of S1P is revered by various concentrations of FTY720, with IC50 effect of 173 nM. In addition, FTY720 (10 nM) alone exerts no effect on the expression of co-stimulatory molecules. FTY720 reverses the increased expression of HLA-I induced by S1P for both the percentages of cells and the MFI, upon comparing the effect of S1P to the effect of combining S1P with FTY720. [1] Medium and high-dose FTY720-P also enhances the levels of TGF-β1. TGF-β1 and Foxp3 mRNA expression are upregulated in the high-dose FTY720-P group. The proliferation of effector T cells is suppressed significantly in the medium and high-dose FTY720-P group at a Treg/Teff cell ratio of 1:1. At a ratio of 1:1, the proliferation of effector T cells is also suppressed in the high-dose FTY720 group. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human U2OS cells NGK2[nJHfW6ldHnvckBie3OjeR?= NWT0OWFRSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBUOVBzIILlZ4VxfG:{IHX4dJJme3OnZDDpckBpfW2jbjDVNm9UKGOnbHzzJINwNWW6cILld5NqdmdiZVfGVEBie3Onc4Pl[EBieyC{ZXPldJRweiCrboTldo5idGm8YYTpc44hcW62bzDjfZRweGyjc32geZNqdmdiSH;lZ4h{fCCmeXWgd5RicW6rbnesJGVEPTB;MD6wNFIh|ryPLh?= NWnpPYU{OjJzMESxOFQ>
CHO cells NYftO4h4TnWwY4Tpc44h[XO|YYm= NGTxfohFcXOybHHj[Y1mdnRib3[gX|M{WF2|cHjpcodwe2mwZTCxJJBpd3OyaHH0[UBnem:vIHj1cYFvKFNzUEGgdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyxiSVO1NF0xNjh2IN88UU4> Mnr2NVU3OTV3MUO=
mouse bone marrow cells MW\DfZRwfG:6aXRCpIF{e2G7 MmHMO|IhcA>? NHraN25EgXSxdH;4bYNqfHliYXfhbY5{fCCEQ2KtRWJNKG[3c3nvckBxem:2ZXnuJFE6OCCneIDy[ZN{cW6pIH3veZNmKGKxbnWgcYFzem:5IHPlcIx{KGGodHXyJFczKGi{czDifUB3cXSjbDDkfYUh\XilbIXzbY9vN2[ub4egZ5l1d22ndILpZ{BidmGueYPpd{whUUN3ME2zMlMh|ryPLh?= NXTLNXFxOjR{N{O2N|I>
human MCF7 cells M1O5VXBzd2yrZnXyZZRqd25iYYPzZZk> MVm3PEBp M3jlWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3PEBpenNiYomgW3NVNTFiYYPzZZktKEmFNUC9OUDPxE1w M3vYfVIyPDV4NUK0
MDA-MB-231 cells NW\ENI1kWHKxbHnm[ZJifGmxbjDhd5NigQ>? NITVeWE4QCCq M17lTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5ODDodpMh[nliV2PUMVEh[XO|YYmsJGlEPTB;IEWg{txONg>? NVzJfoNFOjF2NU[1NlQ>
human SK-BR-3 cells NVXS[HlMWHKxbHnm[ZJifGmxbjDhd5NigQ>? MkXVO|ghcA>? MoH5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVSz3CVk0{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFc5KGi{czDifUBYW1RvMTDhd5NigSxiSVO1NF0hPSEQvF2u NEL5VHYzOTR3NkWyOC=>
human HCT116 cells MnfLVJJwdGmoZYLheIlwdiCjc4PhfS=> MlzGO|ghcA>? MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3PEBpenNiYomgW3NVNTFiYYPzZZktKEmFNUC9OUDPxE1w MnnONlE1PTZ3MkS=
human SW620 cells NIe1Z4NRem:uaX\ldoF1cW:wIHHzd4F6 M{fBfVc5KGh? MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOZNkKwJINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEe4JIhzeyCkeTDXV3QuOSCjc4PhfUwhUUN3ME21JO69VS5? MX6yNVQ2PjV{NB?=
human BLIN-1 cells NUDBXGtJS3m2b4TvfIlkyqCjc4PhfS=> NHiycYI4OiCq NXS5T2lMS3m2b4TvfIlkcXS7IHHnZYlve3RiUHitcoVo[XSrdnWgbJVu[W5iQlzJUk0yKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTD2bZRidCCmeXWg[ZhkdHW|aX;uM4Ztd3diY4n0c41mfHKrYzDhcoFtgXOrczygTWM2OD13LkWg{txONg>? NYHDTmxjOjR{N{O2N|I>
human BV173 cells MmLpR5l1d3SxeHnjxsBie3OjeR?= NWGyR|ZSPzJiaB?= M4ja[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCqLYDvd4l1cX[nIHj1cYFvKEKYMUezJINmdGy|IHHmeIVzKDd{IHjyd{BjgSC4aYThcEBlgWViZYjjcJV{cW:wL3\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyxiSVO1NF03NjNizszNMi=> NXfU[It[OjR{N{O2N|I>
human DU145 cells M2rFV2N6fG:2b4jpZ:Kh[XO|YYm= M4TjdVczKGh? NYPKfG0xS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVYvPSEQvF2u NIXNZYwzPDJ5M{[zNi=>
human SUP-B15 cells NEPXV3JEgXSxdH;4bYPDqGG|c3H5 MWC3NkBp Ml\kR5l1d3SxeHnjbZR6KGGpYXnud5QhWGhvcH;zbZRqfmViaIXtZY4hW1WSLVKxOUBk\WyuczDh[pRmeiB5MjDodpMh[nlidnn0ZYwh\HmnIHX4Z4x2e2mxbj;mcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:Pi56IN88UU4> NF7NUVYzPDJ5M{[zNi=>
human CCRF-CEM cells MknvR5l1d3SxeHnjxsBie3OjeR?= NYjGW|RLPzJiaB?= Mm\aR5l1d3SxeHnjbZR6KGGpYXnud5QhWGhvbnXnZZRqfmViaIXtZY4hS0OURj3DSW0h[2WubIOgZYZ1\XJiN{KgbJJ{KGK7II\peIFtKGS7ZTDlfINtfXOrb36v[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTZwODFOwG0v NWPROGZVOjR{N{O2N|I>
human NALM6 cells Mn2yR5l1d3SxeHnjxsBie3OjeR?= NF;qUlk4OiCq Mlj6R5l1d3SxeHnjbZR6KGGpYXnud5QhWGhvbnXnZZRqfmViaIXtZY4hVkGOTU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVkvPiEQvF2u NUTyO255OjR{N{O2N|I>
human PC3 cells M1n2cmN6fG:2b4jpZ:Kh[XO|YYm= MXG3NkBp Ml7YR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTD2bZRidCCmeXWg[ZhkdHW|aX;uM4Ztd3diY4n0c41mfHKrYzDhcoFtgXOrczygTWM2OD17Lkig{txONg>? NIOz[IIzPDJ5M{[zNi=>
Sf9 insect cells M1;FdWZ2dmO2aX;uJIF{e2G7 MknINUBp NXHBWm9yUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDTNXBNKCh4MjD0c{A2PjhrIHX4dJJme3OnZDDpckBU\jliaX7z[YN1KGOnbHzzJJV{cW6pIGOxVEBieyC|dXLzeJJifGViYX\0[ZIhOSCqch?= MkTVNlQ5ODl6MUS=
human Jurkat cells MWTGeY5kfGmxbjDhd5NigQ>? NF;WWGcyQCCq Mm\kVoV3\XK|YXygc4YhcW6qaXLpeIlwdiCxZjDtbZRw[2ixbnTybYFtKG[3bnP0bY9vKGmwIHj1cYFvKEq3cnvheEBk\WyuczDh[pRmeiBzODDodpMhcW5icILld4Vv[2Vib3[gXk1XSURvZn3r NWDUNZE4OTd2MEC1OVU>
mouse MN9D cells M3zkTGZ2dmO2aX;uJIF{e2G7 NWqxR49OOC5zNjFOwG0> M2HkV|czKGh? M{m3W25mfXKxcILveIVkfGm4ZTDhZ5Rqfmm2eTDpckBud3W|ZTDNUllFKGOnbHzzJIF{e2W|c3XkJIF{KGKub3PrbY5oKG:oIGTOSk1idHCqYTDhd5Nw[2mjdHXkJJRwgGmlaYT5JIF1KDBwMU[geW0h[W[2ZYKgO|IhcHK|IHL5JHRzgXCjbjDicJVmKHO2YXnubY5oNg>? NV7ycFVvOjVyNUCxOlU>
mouse MN9D cells NEm3[VhHfW6ldHnvckBie3OjeR?= NWPyPFE2OC5zNjFOwG0> MkfGNlQhcA>? NIT1ephP\XW{b4Dyc5Rm[3SrdnWgZYN1cX[rdImgbY4hdW:3c3WgUW46TCClZXzsd{Bie3Onc4Pl[EBieyC|dHnteYxifGmxbjDv[kBDTE6IIHX4dJJme3Orb36gZZQhOC5zNjD1UUBi\nSncjCyOEBpenN? MWmyOVA2ODF4NR?=
rat PC12 cells NXHFcXozTnWwY4Tpc44h[XO|YYm= MnLIOUDPxE1? NGf4O5o{OCC2bzCxNlAhdWmwcx?= MnzxTY5lfWO2aX;uJI9nKFCSMlGgZ4F1[Wy7dHnjJJN2[nWwaYSgZYN1cX[rdImgbY4hemG2IGDDNVIh[2WubIOgZZN{\XO|ZXSgZZMheGixc4DoZZRmKGyndnXsJIF1KDVidV2gcYVie3W{ZXSgN|AhfG9iMUKwJI1qdnNw NULPTHJLOjVyNUCxOlU>
mouse MN9D cells MXXGeY5kfGmxbjDhd5NigQ>? Mo\nOUDPxE1? Mn;vTY5lfWO2aX;uJI9nKFCSMlGgZ4F1[Wy7dHnjJJN2[nWwaYSgZYN1cX[rdImgbY4hdW:3c3WgUW46TCClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhifGVibHX2[Ywh[XRiNTD1US=> NULKcWF{OjVyNUCxOlU>

... Click to View More Cell Line Experimental Data

In vivo FTY720 is effective in Ph+ but not Ph- ALL xenografts using an early disease model. FTY720 produces a significant reduction in disease burden in the Ph+ ALL xenografts using an early disease model. Ph+ human ALL xenografts responds to FTY720 with an 80 % reduction in overall disease if treatment has been initiated early on. In contrast, treatment of mice with FTY720 does not result in reduced leukemia compared to controls using four separate human Ph- ALL xenografts. [3]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: Immature DCs
  • Concentrations: 10 nM
  • Incubation Time: 4 hours
  • Method: Immature DCs are left intact or are incubated with 2 μM S1P, 10 nM FTY720, 10 nM SEW2871 or the combinations of S1P with these drugs for 4 hours. As a control 1 μg/mL LPS is used. The cells are washed and incubated in a 96-well plate (v-bottom, 2 × 105 cells per well), washed again and resuspended in PBS buffer containing 0.1% sodium azide. They are labeled with 1 μg/mL FITC-conjugated mouse anti-human CD80, 1 μg/mL FITC-conjugated mouse anti-human CD83, 1 μg/mL FITC-conjugated mouse anti-human CD86, 1 μg/mL FITC-conjugated mouse anti-human HLA-class I, 1 μg/mL FITC-conjugated mouse anti-human HLA-DR, 1 μg/mL FITC-conjugated mouse anti-human HLA-E, or 1 μg/mL FITC-conjugated mouse IgG as a control. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control FITC-conjugated mouse IgG. To stain NK cells with antibodies for various NK cell activating receptors, they are either left untreated or incubated with 2 μM S1P for 4 hours, washed and stained with 1 μg/mL PE-conjugated mouse anti-human NKp30 (CD337), 1 μg/mL PE-conjugated mouse anti-human NKp44 (CD336), 1 μg/mL PE-conjugated mouse anti-human NKG2D (CD314), or as a control 1 μg/mL PE-conjugated mouse IgG1, for 45 min at 4 °C. NK cells are also stained with 1 μg/mL FITC-conjugated anti-killer inhibitory receptor (KIR)/CD158 antibody which recognizes KIR2DL2, KIR2DL3, KIR2DS2 and KIR2DS4, and as a control with FITC-conjugated mouse IgG. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control PE-conjugated or FITC-conjugated mouse IgG.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: NOD/SCIDγc−/− mice bearing ALL cells.
  • Formulation: 2% ethanol or saline
  • Dosages: 5 mg/kg/day, 10 mg/kg/day
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (200.63 mM)
Water 69 mg/mL (200.63 mM)
Ethanol 69 mg/mL (200.63 mM)
In vivo Add solvents individually and in order:
Saline
20 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 343.9
Formula

C19H33NO2.HCl

CAS No. 162359-56-0
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01633112 Active, not recruiting Relapsing-remitting Multiple Sclerosis (RRMS) Novartis Pharmaceuticals|Novartis August 9, 2012 Phase 4
NCT02956200 Not yet recruiting Stroke|Inflammation Second Affiliated Hospital, School of Medicine, Zhejiang University November 2016 Phase 2
NCT02575365 Recruiting Cognition|Brain Volume Loss Novartis Pharmaceuticals|Novartis February 2016 Phase 4
NCT02490930 Recruiting Glioblastoma|Anaplastic Astrocytoma Sidney Kimmel Comprehensive Cancer Center July 2015 Early Phase 1
NCT02939079 Completed Multiple Sclerosis Isfahan University of Medical Sciences|Shiraz University of Medical Sciences April 2015 Phase 2|Phase 3
NCT02373098 Recruiting Relapsing Remitting Multiple Sclerosis Novartis Pharmaceuticals|Novartis March 2015 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

S1P Receptor Signaling Pathway Map

Related S1P Receptor Products

Tags: buy Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl supplier | purchase Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl cost | Fingolimod (FTY720) HCl manufacturer | order Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID